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Abstract
Viral hepatitis and aflatoxin B1 (AFB1) exposure are common risk factors for hepatocellular
carcinoma (HCC). The incidence of HCC in individuals co-exposed to hepatitis C (HCV) or B
virus and AFB1 is greater than could be explained by the additive effect, yet the mechanisms are
poorly understood due to lack of an animal model. This study investigated the outcomes and
mechanisms of combined exposure to HCV and AFB1. We hypothesized that HCV transgenic
(HCV-Tg; expressing core, E1, E2, and p7, nucleotides 342–2771) mice will be prone to
hepatocarcinogenesis when exposed to AFB1. Neonatal (7 days old) HCV-Tg or C57BL/6J wild-
type mice were exposed to AFB1 (6 μg/g bw) or tricaprylin vehicle (15 μl/g bw) and male
offspring were followed for up to 12 months. No liver lesions were observed in vehicle-treated
wild type or HCV-Tg mice. Tumors (adenomas or carcinomas) and preneoplastic lesions
(hyperplasia or foci) were observed in 22.5% (9 of 40) of AFB1-treated wild-type mice. In HCV-
Tg, the incidence of tumorous or pre-tumorous lesions was significantly elevated (50%, 18 of 36),
with the difference largely due to a 2.5-fold increase in the incidence of adenomas (30.5% vs
12.5%). While oxidative stress and steato-hepatisis were observed in both AFB1-treated groups,
molecular changes indicative of the enhanced inflammatory response and altered lipid metabolism
were more pronounced in HCV-Tg mice. In summary, HCV proteins core, E1, E2 and p7 are
sufficient to reproduce the co-carcinogenic effect of HCV and AFB1 which is a known clinical
phenomenon.
Novelty and impact—This work establishes a model for studies of the mechanisms of co-
carcinogenesis of HCV and AFB1 and indicates a crucial role for direct viral protein effects in the
synergy between these factors. A number of molecular pathways known to play a role in liver
carcinogenesis were investigated and the data shows that the HCV structural proteins and AFB1
react synergistically to increase steatosis and tumor incidence whereby HCV and AFB1 may
operate to increase liver cancer incidence through different mechanisms. In addition, while tumor
occurrence may be also linked to lipid peroxidation consequently to AFB1 exposure, we posit that
the conventional explanations (e.g., oxidative stress, lipid accumulation) do not appear to be the
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cause of the synergy and other more specific, but as yet unidentified effects are likely to be
responsible.
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Introduction
Hepatocellular carcinoma (HCC) is the most common type of primary malignancy in the
liver1. Main risk factors of HCC are well-defined and include hepatitis B virus (HBV);
lifestyle, diet and environmental factors (e.g., alcoholic beverages, aflatoxin B1 (AFB1), and
tobacco smoking); and metabolic diseases (e.g., obesity, diabetes and non-alcoholic
steatohepatitis)2. Importantly, the rise in incidence of HCC in the developed countries has
been attributed, at least in part, to an increase in hepatitis C virus (HCV) infections and non-
alcoholic steatohepatitis, pathological states whose prevalence is growing in the US and
Europe3.
While viral hepatitis is estimated to contribute to as many as 90% of HCC cases worldwide4,
several factors have been identified as acting synergistically with both HBV and HCV
infection5. Specifically, dietary exposure to aflatoxins, a class of mycotoxins produced by
moulds of the genus Aspergillus, is a significant risk factor for HCC in less developed
countries with hot and humid climates6. Upon ingestion, AFB1 is metabolized in the liver to
a reactive epoxide that covalently binds on the N7 position of guanine7, leading to
characteristic mutations in cancer-related genes8. Several recent studies provide emerging
epidemiological evidence for the association between AFB1 exposure and advanced liver
disease in HCV-infected patients9,10. In mice, AFB1 is only hepatocarcinogenic when
injected in neonates11 and the incidence of liver neoplasms varies from ~25 to 90%
depending on the mouse strain11–13.
The mechanisms of the synergism between these etiological factors of HCC are not well
understood due to the fact that human HCV is able to cause infection and disease only in
non-human primates14, but not other laboratory animal models, such as mice and rats.
Studies in transgenic mouse models, in which the HCV proteins are expressed, indicate that
HCV is directly pathogenic and oncogenic15, 16. There are several HCV mouse models
varying in the viral proteins being constitutively over-expressed17. While hepatic tumors
have been observed in some of these models15, 16, 18–20, the incidence varies and tumors
develop only in the mice of advanced (>13 months) age. Both HBV12 and H.hepaticus21
have been shown to promote AFB1-induced liver carcinogenesis in mice demonstrating that
co-carcinogenesis due to infectious and chemical factors can be reproduced in the animal
model, but there have been no studies addressing the purported synergism between AFB1
and HCV.
Liver pathology in HCV can result either as a consequence of the immune response or as a
direct effect of viral protein interaction with cellular processes. In this study we
hypothesized that, if direct viral protein effects were responsible for the enhanced
carcinogenesis, the incidence of HCC due to AFB1 would be elevated in HCV transgenic
mice expressing core, E1, E2 and p7 proteins. While expressing viral proteins at levels
comparable to human disease, these mice are immune-tolerant to viral antigens and have no
viral specific adaptive immune response. We demonstrate that the incidence of liver
neoplasia was more than doubled (largely due to an increase in adenomas) in HCV/AFB1
group as compared to AFB1-treated WT mice. Since HCV mice developed no tumors and
exhibited no overt liver pathology at 12 month of age, this observation is indicative of a
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potentiating, but not an additive effect on the molecular pathways to hepatocarcinogenesis.
This study establishes a model for studies of the mechanisms of co-carcinogenesis of HCV




HCV transgenic mice (SL-139 strain, pAlbSVPA-HCV-S, containing the structural genes
core, E1, E2, and p7, nucleotides 342–2771 of HCV genotype 1b, strain N, under the control
of the murine albumin promoter/enhancer) on C57BL/6J (Jackson Laboratory, Bar Harbor,
ME) background were previously reported in Lerat et al16. Transgenic animals were
identified after weaning as detailed in Korenaga et al22. C57BL/6J mice were used as a wild
type (WT) reference strain in all experiments. Neonatal (7 days old) mice were administered
a single dose of AFB1 (6 μg/g bw) or tricaprylin vehicle (15 μl/g bw) by intra-peritoneal
injection. Male mice were maintained on the regular animal chow with free access to food
and water for up to 12 months. Male mice were selected for these studies since male gender
is a risk factor for human HCC4. Three days before sacrifice at 12 month of age, a subset of
mice (5 to 8 per group) were given drinking water containing bromodeoxyuridine (0.2 g/L).
All animal experiments were approved by the UNC Animal Care and Use Committee.
Chemicals
AFB1, tricaprylin, and other chemicals, unless otherwise noted, were obtained from Sigma
(St Louis, MO). AFB1 was dissolved in tricaprylin (400 μg/ml) by heating the solution to
65°C and the solution was then stored at 4°C.
Histopathology
At sacrifice, the livers were examined macroscopically for tumors (carcinomas or
adenomas) and then a section of the liver (including gross lesions) and duodenum were fixed
in neutral buffered formalin. The remainder of the liver tissue was frozen and stored at
−80°C. Histology (from hematoxylin/eosin liver sections) was evaluated by a researcher and
an expert veterinary pathologist in a blinded manner. Incidence and multiplicity of the pre-
neoplastic lesions (hyperplasia or foci) were evaluated using random sections. Microscopic
liver pathology was scored as follows: steatosis (the percentage of hepatocytes containing
fat droplets): <25%=1+, <50%=2+, <75%=3+, >75%=4+; inflammation and necrosis: 1
focus per low-power field=1+, 2=2+, ≥3=3+. Formalin-fixed sections were stained with
Sirius Red to quantify fibrosis. Oil Red O staining was performed on frozen liver sections
(10 μm) to evaluate tissue lipid content.
Immunohistochemistry
Formalin-fixed, paraffin-embedded liver sections (5μm) were deparaffinized, rehydrated,
treated for antigen retrieval and incubated in Peroxidase Blocking Reagent (Dako, 10 min).
Dako EnVision System HRP kit (all antibodies were diluted in saline containing 1% bovine
serum albumin) was used for the detection of bromodeoxyuridine (monoclonal anti-
bromodeoxyuridine antibody, clone Bu20a, Dako, 1:200 dilution, 10 min), 4-
hydroxynonenal (primary rabbit anti-4-HNE antibody, Alpha Diagnostics, San Antonio, TX,
1:500 dilution, 1 h), or F4/80 (primary rat anti-mouse F4/80 antibody, Serotec, Raleigh, NC,
1:200 dilution, 30 min). Quantitative analysis, where applicable, was performed using
Image-Pro® Plus software (Media Cybernetics, Silver Spring, MD) on images at 200×.
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Reduced (GSH) and oxidized (GSSG) glutathione were assessed in liver mitochondria and
whole liver as previously described23 using high performance liquid chromatography. Liver
mitochondria were isolated from ~100 mg of fresh tissue, using Mitochondria Isolation Kit
for Tissue (Pierce, Rockford, IL) following the manufacturer’s instructions (Option A,
protocol 1). The mitochondria were stored −80°C in 250 μl of Mitochondria Isolation
Reagent C containing 10 μg/ml of protease inhibitors cocktail (Pierce).
Determination of hepatic triglycerides content
Hepatic triglycerides were extracted by homogenizing 20 mg of frozen liver tissue in 500 μl
of isopropyl alcohol and 4 μl of the extract was used in subsequent analysis. The level of
triglycerides was determined by using L-Type TG-M Assay Kit (Wako Diagnostic,
Richmond, VA) according to the manufacturer’s instructions.
Quantitative real time reverse polymerase chain reaction
Total RNA was isolated from frozen liver samples using the RNeasy (Qiagen, Valencia,
CA) kit according to the manufacturer’s instructions. RNA concentration and quality were
assessed using ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) and
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), respectively. Ten
micrograms of total RNA were reverse transcribed in a final volume of 100 μl using the
High Capacity Archive kit and random hexamers (Applied Biosystems, Foster City, CA),
diluted 4-fold in water and stored at −80°C. For each sample, 2 μl of cDNA, corresponding
to ~25 ng of reverse transcribed RNA, was analyzed in duplicate, using the
LightCycler®480 Instrument (Roche Applied Science, Indianapolis IN). Primers were
obtained from Applied Biosystems and are listed as Supplemental Table 1. The relative
amount of target gene mRNAs was normalized to internal control Tbp.
Microarray experiments
RNA amplifications and labeling were performed using Low RNA Input Linear
Amplification kits (Agilent Technologies). For hybridization, 750 ng of total RNA from
each mouse liver was amplified and labeled with a fluorescent dye Cy5. In parallel, 750 ng
of a common reference RNA (Icoria Inc., RTP, NC) was labeled with a fluorescent dye Cy3.
Labeled cRNA was then processed, hybridized to Agilent Mouse Toxicology Arrays
(catalog# 4121A, 22,575 features), washed and scanned according to the manufacturer’s
protocol. The resulting images were analyzed by determining the Cy5 fluorescence intensity
of all gene spots (features) on each array using the Agilent Feature Extraction Software
(Version 9.5). Raw data is available from Gene Expression Omnibus (GSE26838). The
median fluorescence intensity of all pixels within one feature was taken as the intensity
value for that feature. The raw intensity values were then normalized using 75th percentile
channel scaling normalization setting of ArrayTrack. The list of differentially expressed
genes was generated using a t-test at p-value <0.01 and a fold change at >1.5. The Ingenuity
Pathway Analysis Software (Ingenuity Systems, Redwood City, CA) was used for pathway
analyses. Ingenuity Pathways Analysis (IPA v. 7.1; Ingenuity Systems, Redwood City, CA)
was used to determine canonical pathways that are enriched by the significant transcripts
identified by the ANCOVA model for each factor.
Mitochondrial DNA damage
Long-polymerase chain reaction method was used to assess integrity of mitochondrial
DNA 24. Primers L15322 (5′-CTCTGGTCTTGTAAACCTG-3′) and H3266 (5′-
CAGGCTGGCAGAAGTAATCAT-3′) yield the product of 4277 bp24, while primers mt316
(forward: 5′-CGACAGCTAAGACCCAAACTGGG-3′, nucleotides 470–492; and reverse
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5′-CCCATTTCTTCCCATTTCATTGGC-3′, nucleotides 785–762) amplify a 316 bp
fragment25. The products were separated on 1% agarose gels and visualized with ethidium
bromide.
Quantification of genomic 8-oxo-deoxyguanine
Capillary liquid chromatography tandem mass spectrometry method was used for detection
of 8-oxo-deoxyguanine adducts in liver DNA isolated and processed as detailed
elsewhere26.
Statistical analysis
The GraphPad Prism software v.5 (GraphPad Software Inc., San Diego, CA) was used for
analyses. Incidence of tumors, steatosis and inflammatory foci between groups were
compared by Fisher’s exact test. In other experiments, unpaired t-test or Welch’s t-test
(when variances were unequal) were used. Quantitative values are expressed as mean ±
standard deviation.
Results
HCV transgene doubled tumor incidence in mice treated with AFB1
All animals treated with AFB1 or vehicle neonatally survived to weaning. A total of 161
male mice were maintained for 6 (n=20), 9 (n=20), or 12 (n=121) months. No neoplastic or
pre-neoplastic lesions were observed in WT and HCV-Tg mice treated with the vehicle
alone at any of the three time points (Table 1). Liver neoplasias were found only in 12-
month old animals treated with AFB1, with an incidence of 22.5% in WT, and 50% (p<0.05)
in HCV-Tg group, indicating a potentiating effect. In HCV-Tg/AFB1 mice, increased
incidence of liver neoplasms was mainly due to a significantly greater (p<0.05) incidence of
liver adenomas. While transgene expression varied between individual mice in HCV-Tg
groups, tumor incidence did not correlate with the viral protein levels (data not shown). In
both wild-type and HCV-Tg mice, all types of neoplasms (e.g., hyperplasia, foci, adenoma
and carcinoma) were observed (Supplemental Figure 1, Table 1) and there was no difference
in tumor multiplicity. Interestingly, three different subtypes of liver adenomas (vacuolated,
well-differentiated and basophilic focus-like) were observed in both groups (Supplemental
Figure 1).
Effects of HCV-Tg and AFB1 on liver inflammation and steatosis
Hepatic steatosis and inflammation are commonly observed in patients with HCV27. HCV-
Tg mice also develop steatosis which is thought to be mediated by HCV core protein28, 29.
There are reports that AFB1 exposure leads to steatohepatitis in humans30, rats31, and
mice32. Thus, we evaluated liver histopathology, cell proliferation, as well as markers of
oxidative stress and steatosis.
In vehicle treated animals, mild inflammatory and steatotic changes were observed in some,
but not all animals, with most of the changes manifesting in 12-month old mice (Table 1).
Interestingly, HCV-Tg mice showed no difference from WT in either incidence or severity
of the liver histopathological changes. In AFB1-treated mice, no adverse liver pathology
was observed in 6- or 9-months groups; however, at 12 months, HCV-Tg/AFB1 mice
exhibited greater inflammatory change than WT/AFB1 mice. It should be noted, however,
that these lesions were comprised of small lobular inflammatory foci which are different
from the portal-based inflammatory lesions observed in human HCV patients.
Furthermore, liver steatosis, as evidenced from the histopathological evaluation (Table 1,
Figure 1A), Oil Red O staining (Figure 1A) and hepatic triglyceride content (Figure 1B),
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was observed in both AFB1 groups at 12 months. Concomitantly, the extent of hepatic lipid
peroxidation, as evidenced by presence of 4-hydroxynonenal-adducted proteins, was also
elevated at 12 months (Figure 1C).
Interestingly, cell proliferation rate in non-tumoral liver tissue was increased in response to
AFB1 treatment at 12 months in WT, but not HCV-Tg groups (Figure 2A). An elevation in
the number of F4/80-positive macrophages in the liver was also observed in WT, but not
HCV-Tg mice in response to AFB1 (Figure 2B). Even though a significant elevation in
expression of alpha-smooth muscle actin, transcription growth factor beta 1 or its receptor
were observed in WT/AFB1 group, no effect was observed in HCV-Tg mice (Figures 2C, E
and F). Furthermore, no evidence of liver fibrosis was found using histological examination,
Sirius red staining (Figure 2G), or expression of collagen 1-alpha 1 (Figure 2D).
Since an increase in lipid peroxidation was observed in AFB1-treated mice (Figure 1C), we
further examined markers of oxidative stress (Figure 3). In whole liver, we examined
oxidative damage to genomic DNA (8-oxo-dG and expression of base excision DNA repair
genes 8-oxo-dG DNA glycosylase 1 and polymerase beta 1) and amounts of reduced and
oxidized glutathione (Figure 3A), yet no effect of either AFB1 or HCV-Tg was observed.
Next, we evaluated mitochondrial DNA damage and glutathione content (Figure 3B) and
also found no difference between the groups.
Effects of HCV and AFB1 on liver lipid metabolism pathways
To evaluate the effects of AFB1 and HCV on lipid metabolism pathways, we first examined
several factors previously associated with fatty acid and triglyceride metabolism in HCV
transgenic mice. We evaluated expression of lipid catabolism, lipoprotein secretion, lipid
uptake and lipogenesis genes (Figures 4A–D). Concomitant with little evidence for fatty
change in the liver of vehicle-treated HCV-Tg mice, we observed no differences between
WT and HCV-Tg groups. Our data shows that the mechanisms for excess fat accumulation
may differ between WT/AFB1 and HCV-Tg/AFB1 groups. For example, while AFB1
induced lipogenesis in WT, lipid secretion and uptake were dysregulated in HCV-Tg mice.
Next, we examined liver gene expression profiles in each experimental group to assess
global differences in the molecular pathways that may be affected by each experimental
factor (Figure 5). While both AFB1 and HCV transgene had an effect of the liver
transcriptome when compared to the WT group (Figure 5A), the overlap between the
groups, in terms of the individual genes, was relatively small. Interestingly, the greatest
effect of AFB1 treatment in wild-type mice was on the inflammatory response network
(Figure 5B), an effect which appears to be synergistic with the impact on immune cell
trafficking pathways of HCV-Tg alone (Figure 5C), or a combination of the two (Figure
5D). Lipid metabolism genes, largely related to the inflammatory cytokines, were induced in
HCV-Tg/AFB1 mice as compared to WT (Figure 5E).
Unfolded protein response (UPR) is not induced by either HCV or AFB1
It has been shown that HCV envelope proteins induce UPR, a cellular response to
accumulation of damaged proteins in the endoplasmatic reticulum, in vitro33. Several in vivo
studies using HCV transgenic mouse models, however, showed little evidence for induction
of UPR in the liver34 in absence of additional factors, such as iron overload35. Interestingly,
a link between the UPR and hepatic steatosis has also been proposed36. Thus, we examined
whether AFB1 may have an effect on UPR in WT or HCV-Tg mice. Similar to the
observation of others34, we found no evidence that UPR is affected by either HCV, AFB1 or
both (Figure 4E).
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An interaction between AFB1 exposure and HBV infection on HCC occurrence is a well-
established phenomenon confirmed by multiple well-controlled epidemiological
studies37, 38. Data from several recent reports from the Middle East and South-East
Asia9, 10, 39, where both HCV prevalence and dietary exposure to AFB1 are high, also
suggests that AFB1 exposure may be associated with advanced liver disease and increased
HCC incidence in HCV-infected patients. Our study shows that HCV proteins core, E1, E2
and p7 are sufficient to reproduce the co-carcinogenic effect of HCV and AFB1 in the
mouse, opening a possibility for understanding the molecular mechanisms of the interaction.
Much progress has been made in elucidating the mechanisms that underlie AFB1 and HCV
hepatocarcinogenesis. Biotransformation of AFB1 to the putative carcinogenic intermediate,
AFB-8,9-exo-epoxide, is a key step in the formation of pro-mutagenic DNA lesions40.
Detoxification of AFB-8,9-epoxide by glutathione S-transferases is an important protective
mechanism in mice41, species resistant to AFB1 hepato-carcinogenesis if treated post-
neonataly11. Chronic inflammation, a result of HCV infection, was suggested to contribute
to both DNA damage and cell proliferation in the liver, processes that may accelerate both
accumulation of the mutations and clonal expansion of the initiated cells42. Firm molecular
evidence in support of this hypothesis from subjects exposed to HCV and AFB1 is,
however, lacking.
Several HCV transgenic mouse models have been developed in the past decade, yet liver
tumors have been observed only in a couple of strains, usually after 13 to 24 months15, 18.
Most of the HCV transgenic mouse models exhibit a limited overt liver phenotype, even late
in life17, yet are susceptible to a number of additional hepatotoxic challenges (e.g., iron
overload43 or alcohol20). An HCV-Tg mouse model which shows no spontaneous liver
tumor development, yet exhibits an oxidative mitochondrial phenotype22, was selected here
to study AFB1/HCV co-carcinogenic effect. We posit that the animal which does not have
liver disease, yet is susceptible to additional challenges, may be relevant to model the human
carriers of HCV who have not manifested with hepatitis but may be at risk for HCC upon
exposure to AFB1.
Our data suggest that the molecular pathways of promotion of AFB1-induced carcinogenesis
may differ between wild-type and HCV-Tg mice. We observed an increase in cell
proliferation and expression of pro-fibrotic cytokines in the WT/AFB1, but not the HCV-Tg/
AFB1 group. Conversely, AFB1 treatment in HCV-Tg mice, as compared to WT/AFB1
group, led to a significant increase in hepatic inflammation and expression of immune cell
trafficking genes. These differences illustrate that while the gross liver pathology observed
in AFB1-treated mice (e.g., steatosis and lipid peroxidation) are similar between the groups,
the molecular events leading to steatohepatitis and tumor promotion are impacted greatly by
the HCV.
The effects of HCV on lipid metabolism are well documented in human studies29, a
phenomenon also observed in some HCV-Tg models28, 34. Steatohepatitis also appears to
play a role in promoting HCV replication27. However, not all HCV-infected patients, or
HCV transgenic mouse strains, manifest with steato-hepatitis, or even steatosis, and it is also
difficult to distinguish between the pathways that may lead to lipid accumulation in the liver.
For example, studies using different HCV transgenic mouse models have reported enhanced
fatty acid uptake and decreased mitochondrial beta-oxidation28, as well as increased
lipogenesis and decreased triglyceride secretion34, all of which may contribute to this
phenotype. In the HCV-Tg model used here, lipid accumulation in the liver was minimal in
absence of AFB1 treatment, yet HCV transgene sensitized hepatocytes to steatosis induced
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by AFB1. AFB1 has been reported to cause fatty change in the liver in humans30, rats31 and
mice32; however, no mechanism has been proposed. While our study did not address this
issue in full, we show that the steatosis-promoting effect of AFB1 may also differ between
WT and HCV-Tg mice. This was evidenced by changes in expression of the lipogenesis
gene fatty acid synthase in the WT group, but additional transcripts for fatty acid translocase
and microsomal transfer protein, involved in lipid uptake and lipoprotein secretion, were
induced by AFB1 in HCV-Tg mice.
We also observed an increase in lipid peroxidation in AFB1-treated mice even though no
changes in genomic or mitochondrial oxidative DNA damage or intracellular or
mitochondrial glutathione were found. Moriya et al.44 previously showed that no lipid
peroxidation is found in HCV-Tg mice until 16 months of age when the mice begin to
develop HCC. Moreover, they also observed lipid peroxidation in young HCV mice if
treated with alcohol or carbon tetrachloride indicating that the HCV core protein predisposes
hepatocytes to oxidative stress44. Thus, our study suggests that AFB1 challenge in HCV-Tg
and WT mice promotes lipid peroxidation which is most pronounced when tumors are
observed.
It should be noted that an alternative explanation for the observed differences in the
incidence of AFB1-induced neoplastic and pre-neoplastic liver lesions between WT and
HCV-Tg mice is that AFB-DNA adduct formation or removal in neonatal mice could have
been effected by the transgene. Even though a comparison of liver gene expression data
between WT and HCV-Tg mice at 12 months of age showed no difference in transcript
levels for AFB1 metabolizing enzymes, additional experiments examining the time course
of AFB1 DNA damage in neonates are necessary to address this possible mechanism.
In conclusion, while HCV mice exhibit a phenotype similar to wild-type mice at 12 months,
they are susceptible to AFB1 exposure. We show that the HCV structural proteins potentiate
carcinogenesis by AFB1 via increases in steatosis and tumor incidence; however, HCV and
AFB1 may operate to increase liver cancer incidence through different mechanisms. In
addition, while tumor occurrence may be also linked to lipid peroxidation consequently to
AFB1 exposure, we posit that the conventional explanations (e.g., oxidative stress, lipid
accumulation) do not appear to be the cause of the observed effect and other more specific,
but as yet unidentified effects are likely to be responsible.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments





HCV hepatitis C virus
HCV-Tg HCV transgenic mouse
HBV hepatitis B virus
Jeannot et al. Page 8













Tbp TATA box binding protein
UPR unfolded protein response
References
1. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 2007; 132:2557–76. [PubMed: 17570226]
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends.
Gastroenterology. 2004; 127:S5–S16. [PubMed: 15508102]
3. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT. Incidence rates of hepatocellular carcinoma
in the U.S. and Denmark: recent trends. Int J Cancer. 2007; 121:1624–6. [PubMed: 17557292]
4. International Agency for Research on Cancer. World Cancer Report 2008. Lyon, France: IARC
Press; 2008.
5. London WT, Evans AA, McGlynn K, Buetow K, An P, Gao L, Lustbader E, Ross E, Chen G, Shen
F. Viral, host and environmental risk factors for hepatocellular carcinoma: a prospective study in
Haimen City, China. Intervirology. 1995; 38:155–61. [PubMed: 8682610]
6. International Agency for Research on Cancer. Some Naturally Occurring Substances: Food Items
and Constituents, Heterocyclic Aromatic Amines and Mycotoxins. Lyon, France: IARC Press;
1993.
7. Garner RC, Miller EC, Miller JA. Liver microsomal metabolism of aflatoxin B1 to a reactive
derivative toxic to Salmonella typhimurium TA 1530. Cancer Res. 1972; 32:2058–66. [PubMed:
4404160]
8. Foster PL, Eisenstadt E, Miller JH. Base substitution mutations induced by metabolically activated
aflatoxin B1. Proc Natl Acad Sci U S A. 1983; 80:2695–8. [PubMed: 6405385]
9. Chen CH, Wang MH, Wang JH, Hung CH, Hu TH, Lee SC, Tung HD, Lee CM, Changchien CS,
Chen PF, Hsu MC, Lu SN. Aflatoxin exposure and hepatitis C virus in advanced liver disease in a
hepatitis C virus endemic area in Taiwan. Am J Trop Med Hyg. 2007; 77:747–52. [PubMed:
17978082]
10. Sayed HA, El Ayyat A, El Dusoki H, Zoheiry M, Mohamed S, Hassan M, El Assaly N, Awad A,
El Ansary M, Saad A, El Karim AA. A cross sectional study of hepatitis B, C, some trace
elements, heavy metals, aflatoxin B1 and schistosomiasis in a rural population, Egypt. J Egypt
Public Health Assoc. 2005; 80:355–88. [PubMed: 16900614]
11. Vesselinovitch SD, Mihailovich N, Wogan GN, Lombard LS, Rao KV. Aflatoxin B 1, a
hepatocarcinogen in the infant mouse. Cancer Res. 1972; 32:2289–91. [PubMed: 4343225]
12. McGlynn KA, Hunter K, LeVoyer T, Roush J, Wise P, Michielli RA, Shen FM, Evans AA,
London WT, Buetow KH. Susceptibility to Aflatoxin B1-related Primary Hepatocellular
Carcinoma in Mice and Humans. Cancer Res. 2003; 63:4594–601. [PubMed: 12907637]
13. Liu SP, Li YS, Lee CM, Yen CH, Liao YJ, Huang SF, Chien CH, Chen YM. Higher susceptibility
to aflatoxin B(1)-related hepatocellular carcinoma in glycine N-methyltransferase knockout mice.
Int J Cancer. 2011; 128:511–23. [PubMed: 20473876]
14. Bradley DW. Studies of non-A, non-B hepatitis and characterization of the hepatitis C virus in
chimpanzees. Curr Top Microbiol Immunol. 2000; 242:1–23. [PubMed: 10592653]
15. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S,
Miyamura T, Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in
transgenic mice. Nat Med. 1998; 4:1065–7. [PubMed: 9734402]
16. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman
SA, Lemon SM. Steatosis and liver cancer in transgenic mice expressing the structural and
nonstructural proteins of hepatitis C virus. Gastroenterology. 2002; 122:352–65. [PubMed:
11832450]
17. Koike K, Moriya K, Matsuura Y. Animal models for hepatitis C and related liver disease. Hepatol
Res. 2010; 40:69–82. [PubMed: 20156300]
Jeannot et al. Page 9













18. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma.
Gastroenterology. 2004; 127:S62–S71. [PubMed: 15508105]
19. Naas T, Ghorbani M, Alvarez-Maya I, Lapner M, Kothary R, De Repentigny Y, Gomes S, Babiuk
L, Giulivi A, Soare C, Azizi A, Diaz-Mitoma F. Characterization of liver histopathology in a
transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and
2. J Gen Virol. 2005; 86:2185–96. [PubMed: 16033966]
20. Machida K, Tsukamoto H, Mkrtchyan H, Duan L, Dynnyk A, Liu HM, Asahina K, Govindarajan
S, Ray R, Ou JH, Seki E, Deshaies R, et al. Toll-like receptor 4 mediates synergism between
alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U
S A. 2009; 106:1548–53. [PubMed: 19171902]
21. Fox JG, Feng Y, Theve EJ, Raczynski AR, Fiala JL, Doernte AL, Williams M, McFaline JL,
Essigmann JM, Schauer DB, Tannenbaum SR, Dedon PC, et al. Gut microbes define liver cancer
risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut. 2010; 59:88–97.
[PubMed: 19850960]
22. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, Weinman SA. Hepatitis C Virus Core
Protein Inhibits Mitochondrial Electron Transport and Increases Reactive Oxygen Species (ROS)
Production. J Biol Chem. 2005; 280:37481–8. [PubMed: 16150732]
23. James SJ, Rose S, Melnyk S, Jernigan S, Blossom S, Pavliv O, Gaylor DW. Cellular and
mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with
autism. FASEB J. 2009; 23:2374–83. [PubMed: 19307255]
24. Milano J, Day BJ. A catalytic antioxidant metalloporphyrin blocks hydrogen peroxide-induced
mitochondrial DNA damage. Nucleic Acids Res. 2000; 28:968–73. [PubMed: 10648790]
25. Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M, Letteron P, Degott C,
Feldmann G, Pessayre D, Fromenty B. Impaired adaptive resynthesis and prolonged depletion of
hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology. 2002;
123:1278–90. [PubMed: 12360488]
26. Powell CL, Kosyk O, Ross PK, Schoonhoven R, Boysen G, Swenberg JA, Heinloth AN, Boorman
GA, Cunningham ML, Paules RS, Rusyn I. Phenotypic anchoring of acetaminophen-induced
oxidative stress with gene expression profiles in rat liver. Toxicol Sci. 2006; 93:213–22. [PubMed:
16751229]
27. Piver E, Roingeard P, Pages JC. The cell biology of hepatitis C virus (HCV) lipid addiction:
molecular mechanisms and its potential importance in the clinic. Int J Biochem Cell Biol. 2010;
42:869–79. [PubMed: 20067842]
28. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T. PPARalpha activation is
essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J
Clin Invest. 2008; 118:683–94. [PubMed: 18188449]
29. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic
data. Liver Int. 2009; 29 (Suppl 2):26–37. [PubMed: 19187070]
30. Colon AR. Hepatic steatosis in children. Am J Gastroenterol. 1977; 68:260–9. [PubMed: 413433]
31. Sachan DS, Yatim AM. Suppression of aflatoxin B1-induced lipid abnormalities and
macromolecule-adduct formation by L-carnitine. J Environ Pathol Toxicol Oncol. 1992; 11:205–
10. [PubMed: 1380553]
32. Ankrah NA, Addo PG, Abrahams CA, Ekuban FA, Addae MM. Comparative effects of aflatoxins
G1 and B1 at levels within human exposure limits on mouse liver and kidney. West Afr J Med.
1993; 12:105–9. [PubMed: 8398929]
33. Chan SW, Egan PA. Hepatitis C virus envelope proteins regulate CHOP via induction of the
unfolded protein response. FASEB J. 2005; 19:1510–2. [PubMed: 16006626]
34. Lerat H, Kammoun HL, Hainault I, Merour E, Higgs MR, Callens C, Lemon SM, Foufelle F,
Pawlotsky JM. Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in
transgenic mice. J Biol Chem. 2009; 284:33466–74. [PubMed: 19808675]
35. Nishina S, Korenaga M, Hidaka I, Shinozaki A, Sakai A, Gondo T, Tabuchi M, Kishi F, Hino K.
Hepatitis C virus protein and iron overload induce hepatic steatosis through the unfolded protein
response in mice. Liver Int. 2010; 30:683–92. [PubMed: 20214734]
Jeannot et al. Page 10













36. Rutkowski DT, Wu J, Back SH, Callaghan MU, Ferris SP, Iqbal J, Clark R, Miao H, Hassler JR,
Fornek J, Katze MG, Hussain MM, et al. UPR pathways combine to prevent hepatic steatosis
caused by ER stress-mediated suppression of transcriptional master regulators. Dev Cell. 2008;
15:829–40. [PubMed: 19081072]
37. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, Wang J, Wu Y, Liu G, Wu Y, Zhu Y. Increased
risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis
who have detectable urinary aflatoxin metabolite M1. Hepatology. 1999; 30:379–83. [PubMed:
10421643]
38. Yu MW, Lien JP, Chiu YH, Santella RM, Liaw YF, Chen CJ. Effect of aflatoxin metabolism and
DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan.
J Hepatol. 1997; 27:320–30. [PubMed: 9288607]
39. Anwar WA, Khaled HM, Amra HA, El Nezami H, Loffredo CA. Changing pattern of
hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat
Res. 2008; 659:176–84. [PubMed: 18346933]
40. Eaton DL, Gallagher EP. Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol.
1994; 34:135–72. [PubMed: 8042848]
41. Ilic Z, Crawford D, Vakharia D, Egner PA, Sell S. Glutathione-S-transferase A3 knockout mice are
sensitive to acute cytotoxic and genotoxic effects of aflatoxin B1. Toxicol Appl Pharmacol. 2010;
242:241–6. [PubMed: 19850059]
42. Kensler TW, Roebuck BD, Wogan GN, Groopman JD. Aflatoxin: A 50 Year Odyssey of
Mechanistic and Translational Toxicology. Toxicol Sci. 2011 in press.
43. Furutani T, Hino K, Okuda M, Gondo T, Nishina S, Kitase A, Korenaga M, Xiao SY, Weinman
SA, Lemon SM, Sakaida I, Okita K. Hepatic iron overload induces hepatocellular carcinoma in
transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology. 2006; 130:2087–
98. [PubMed: 16762631]
44. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T,
Ishibashi K, Horie T, Imai K, Todoroki T, et al. Oxidative stress in the absence of inflammation in
a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. 2001; 61:4365–
70. [PubMed: 11389061]
Jeannot et al. Page 11













Figure 1. Liver steatosis in WT and HCV-Tg mice treated with AFB1
(A) Representative hematoxylin-eosin and Oil Red O stained sections (100x magnification)
from 12 months old animals of WT/AFB1 and HCV-Tg/AFB1 groups showing mixed
macrovesicular and microvesicular characteristics of steatosis. (B) Hepatic triglyceride
content in 12 months old animals. Asterisks (* and **) denote statistical significance
(p<0.05 and p<0.01, respectively; n=18–37 per group) between the groups as indicated. (C)
Representative photomicrographs (100x) of 4-hydroxy-nonenal stained liver sections.
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Figure 2. Hepatocyte proliferation, inflammation and fibrosis markers
(A) Percent BrDU-positive nuclei (n=4–8/group; mean±standard deviation for 5 randomly
selected fields at 200x); (B) area occupied by F4/80-stained cells (n=9–16/group; mean
±standard deviation for 10 randomly selected fields at 100x) relative to WT group. Liver
expression (evaluated using real-time PCR and normalized to levels in WT group; n=6–16/
group) of smooth muscle actin-alpha (C), collagen 1-alpha1 (D), transforming growth factor
beta1 (E) and its receptor (F). Asterisks (*, ** and ***) denote statistical significance
(p<0.05, p<0.01 and p<0.001, respectively) between the groups as indicated. (G)
Representative Sirius red-stained sections (100x) from 12 months old animals of WT/AFB1
and HCV-Tg/AFB1 groups.
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Figure 3. Liver oxidative stress in WT and HCV-Tg mice treated with AFB1
(A) In whole liver samples, genomic DNA content of 8-oxo-dG adducts, reduced
glutathione, reduced to oxidized glutathione ratio, and expression of base-excision DNA
repair genes 8-oxo-dG DNA glycosylase and polymerase beta were assessed. (B) In hepatic
mitochondria, mtDNA integrity, and levels of reduced glutathione, or reduced to oxidized
glutathione ratio were evaluated. No significant differences were observed (n=5–10/group).
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Figure 4. Lipid metabolism and UPR response gene expression in livers of WT and HCV-Tg
mice treated with AFB1
(A–D) The expression of lipid metabolism genes subdivided into various categories as
shown, as well as (E) genes playing a role in UPR response, was determined by real-time
PCR and expression was normalized to WT group. Asterisks (* and **) denote statistical
significance (n=5–8/group; p<0.05 and p<0.01, respectively) between the groups as
indicated.
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Figure 5. Microarray analysis of liver tissues from WT and HCV-Tg mice treated with AFB1
(A) Venn diagram showing genes that were significantly different between the groups as
indicated. The number of genes in each comparison is shown. (B–E) Molecular network
interactions between the genes significantly different between each group (as indicated)
were visualized using Ingenuity® database. Up-regulated genes are identified in red, down-
regulated in green.
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